Objective
Vaccination in the SARS-CoV-2 pandemic is important, especially to protect pregnant women and the unborn. In 2021, the messenger RNA (mRNA)-based vaccines BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna), and the vector-based vaccine AZD1222 (AstraZeneca) were approved for use in Germany. Vaccination for pregnant women was considered after weighing the individual benefits and risks of the vaccines without preference for a vaccine type. After national guidelines discouraged the use of AZD1222 in those under 60 years of age, mRNA-based boost vaccination was recommended. In this study we intend to evaluate antibody kinetics following heterologous vaccination in pregnant women in comparison to their newborns as well as to a healthy nonpregnant control group.
Study Design
We recruited 3 pregnant participants (gestational age at primary vaccination between 21 and 28 weeks) and 25 nonpregnant control participants at the Jena University Hospital. They were observed after prime vaccination with AZD1222 and boost vaccination 12 weeks thereafter with either BNT162b2 or mRNA-1273. Ethical approval was obtained for the same (Jena University Hospital ethics commission ref.: 2021-2078). The anti-Spike immunoglobulin G (IgG) antibody levels were determined in the serial serum samples (before and 1, 2, 3, 4, 5, 8, and 16 weeks after prime vaccination) and, if available, in the maternal and cord serum at the time of birth using the LIAISON SARS-CoV-2 TrimericS IgG assay on the Liaison XL chemiluminescence analyzer (DiaSorin, Saluggia, Italy), according to the manufacturer’s instructions. The neutralization capacity was tested in a neutralization assay using Vero-76 cells and a SARS-CoV-2 strain isolated from a respiratory specimen (SARS-CoV-2/hu/Germany/Jena-vi005588/2020), utilizing WST-1 (CELLPRO-RO, Roche, Basel, Switzerland) to quantify cell viability after infection. The neutralization titer was defined as the inverted maximal dilution at which ≥50% of the cytopathic effect caused by the virus was neutralized (ID 50 ). For the pregnant participants, the recomLine SARS-CoV-2 IgG immunoblot (Mikrogen, Neuried, Germany) was performed 16 weeks after the initial vaccination to rule out interfering infection by measuring the nucleocapsid IgG antibodies.
Results
The SARS-CoV-2 Spike IgG antibodies were detected for all the study participants ( Figure ), with ID 50 (inhibitory serum dilution showing a 50% neutralization of the viral effects on cell viability) neutralization titers ≥160 in maternal and cord serum samples. The immunoblot showed distinct signals in both the receptor-binding domain and the Spike subunit 1 IgG for all the pregnant participants, but showed no signal for nucleocapsid antibodies. Severe adverse events requiring hospitalization were not reported during the observational period, and all the 3 pregnant participants delivered at term.
